This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Dexamethasone intravitreal implant (Ozurdex) for non-infectious posterior uveitis

< Back

Dexamethasone intravitreal implant (Ozurdex) for non-infectious posterior uveitis


Eye Disease

December 2010

Dexamethasone intravitreal implant (Ozurdex, Dexamethasone intravitreal implant in applicator) is a system that delivers a sustained release formulation of dexamethasone to the posterior segment of the eye. Dexamethasone is a corticosteroid which has anti- inflammatory and anti-vascular endothelial growth factor (VEGF) properties 4. Dexamethasone intravitreal implant is intended to replace current localised treatments and is administered by intravitreal injection every 6 months. One implant contains 700?g of dexamethasone 5.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts